First-in-Class Drug Launched for Hereditary Angioedema
Salix and Pharming Group NV announced the launch of Ruconest (C1 esterase inhibitor [recombinant]) injection for the treatment of acute angioedema attacks in patients with hereditary angioedema (HAE).
Ruconest is >98% pure and does not carry any known risk of virus transmission that can be found in human plasma. The primary function of C1 esterase inhibitor is to regulate the activation of the complement and contact system pathways. Regulation of these systems is performed through the formation of complexes between the protease and the inhibitor, resulting in inactivation of both and consumption of the C1 esterase inhibitor.
Ruconest is available as a 50 IU/kg strength in 25mL single-use vials containing 2100 IU rhC1INH lyophilized powder.
For more information call (855) 613-4HAE or visit Ruconest.com.